Cardiology Research Dubrava Prospective Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: SGLT-2 inh therapy, CIED implantation, thromboaspiration,.
- Who it may be relevant to
- Registry conditions: Heart Failure, Arrhythmias, Cardiac, Atrial Fibrillation, Acute Coronary Syndrome. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Croatia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Cardiology Research Dubrava: Single Centre, Prospective Registry
Overview
Cardiology Research Dubrava registry is a prospective, single centre registry including patients with acute coronary syndrome with and without ST segment elevation, patients with heart failure who were prescribed with SGLT-2 inhibitors, patients implanted with TAVI, patients with venous thromboembolism, patients with pulmonary embolism who underwent thromboaspiration procedure, patients implanted with ICD, CRT and conduction system pacing devices, as well as patients with atrial fibrillation who underwent pulmonary vein isolation and are prescribed with long-term anticoagulation therapy.
Detailed description
Cardiology Research Dubrava registry is a prospective, single centre registry including patients with acute coronary syndrome with and without ST segment elevation, patients with heart failure who were prescribed with SGLT-2 inhibitors, patients implanted with TAVI, patients with venous thromboembolism, patients with pulmonary embolism who underwent thromboaspiration procedure, patients implanted with ICD, CRT and conduction system pacing devices, as well as patients with atrial fibrillation who underwent pulmonary vein isolation and are prescribed with long-term anticoagulation therapy.
In this long-term follow-up registry we plan to collect data on clinical status, standard laboratory results including lipidogram values, NTproBNP values after specific interventions (in.ex. TAVI implantation, SGLT2inh prescripition), bleeding complications, and every major cardiovascular event, including cardiovascular death and all cause death.
Interventions
- Other SGLT-2 inh therapy, CIED implantation, thromboaspiration,
long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
Primary outcome measures
- cardiovascular death [Time frame: 10 years]
- freedom from atrial arrhythmias [Time frame: 10 years]
- Time to revascularization [Time frame: 10 years]
- Bleeding complications [Time frame: 10 years]
- Laboratory levels of NTproBNP [Time frame: 10 years]
Eligibility criteria
Inclusion Criteria: patients implanted with CIED, or with VTE, or with ACS or with TAVI -
Exclusion Criteria: non compliance, not undergoing follow-up at this center
\-
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Croatia · 1 center
- Dubrava University Hospital — Zagreb
Publications
- Radic M, Jurin I, Rode F, Simunovic L, Kolundzic P, Hadzibegovic I, Manola S, Vitlov P, Ivanovic Mihajlovic V, Grizelj D, Falak H, Udovicic M, Letilovic T. Heart Failure Etiology and 6-Month Cardiorenal Recovery Patterns After Early In-Hospital SGLT2 Inhibitor Initiation in HFrEF: A Prospective Real-World Cohort. Medicina (Kaunas). 2026 May 24;62(6):1017. doi: 10.3390/medicina62061017. PMID 42356030
Identifiers
NCT: NCT06090591 · DUH-012017